By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


KaloBios Pharmaceuticals, Inc. 

260 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-243-3100 Fax: 650-243-3260



Company News
KaloBios (KBIO) CEO To Participate In Pharmaceutical Strategy Conference 9/27/2016 7:41:42 AM
KaloBios (KBIO) Now Current On SEC Periodic Filings 9/26/2016 7:58:41 AM
KaloBios (KBIO) Files Outstanding 10-Q And 10-K for 2015 9/2/2016 8:06:37 AM
KaloBios (KBIO), Post-Shkreli, Vows 'Maniacal' Focus On R&D And Transparency 8/30/2016 7:07:58 AM
Martin Shkreli Sells Remaining Stake of Bay Area's KaloBios (KBIO) 8/29/2016 7:49:13 AM
KaloBios (KBIO) Announces First Patient Dosed In Phase I Study Of Lenzilumab For The Treatment Of Chronic Myelomonocytic Leukemia 7/25/2016 8:56:08 AM
The People Who Made the Most Cash Off of KaloBios (KBIO)'s Bankruptcy Filing 7/21/2016 6:53:58 AM
KaloBios (KBIO) Enters Deal to Buy Back Former CEO Martin Shkreli's Shares 7/7/2016 5:51:24 AM
KaloBios (KBIO) Emerges from Chapter 11 Bankruptcy, Buys Tropical Disease Drug 7/1/2016 8:06:18 AM
Trio of Execs that Saved Martin Shkreli's Old Company KaloBios (KBIO) Could Get $700,000 Award 6/2/2016 6:55:01 AM